Clinical Trials Logo

Clinical Trial Summary

This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05027828
Study type Observational
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status Not yet recruiting
Phase
Start date September 1, 2021
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04555369 - The Value of ctDNA on Chemotherapy Efficacy for mCRC N/A
Not yet recruiting NCT03688035 - Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Recruiting NCT03737539 - Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Stage II-III Colorectal Cancer After Radical Resection
Not yet recruiting NCT04511559 - Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
Recruiting NCT03748680 - IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer Phase 2
Completed NCT02620527 - Concordance Between ctDNA Assay and FoundationOne
Active, not recruiting NCT04276337 - Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
Recruiting NCT04456972 - Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers. N/A
Recruiting NCT03750175 - OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
Recruiting NCT04457297 - Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection Phase 3
Suspended NCT04434040 - Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) Phase 2
Recruiting NCT03615170 - Application of Circulating Tumor DNA Test in the Diagnosis and Treatment of Patients With Advanced Rectal Cancer
Recruiting NCT04530890 - Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer N/A
Withdrawn NCT03770299 - An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease Phase 2
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Recruiting NCT03481101 - WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC N/A
Not yet recruiting NCT04966663 - Using ctDNA to Determine Therapies for Lung Cancer Phase 2
Completed NCT04560270 - CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer N/A